Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy

NCT06649565

Breast Cancer

RECRUITING

Clinical Validation of an Artificial Intelligence Algorithm to Help Interpret Mammograms

NCT05640011

Breast Cancer

COMPLETED

Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography

NCT03708978

Women With Breast Cancer

COMPLETED

The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates Classification of Breast Lessions

NCT05892380

Breast Cancer

UNKNOWN

Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer

NCT07063667

Breast Cancer, Metastatic Artifical Intelligence

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

non respondants of neo treatment

those patients with no response or partial response when administered with Chemotherapy prior to sugery

The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer

Intervention Type OTHER

Evaluate response to neoadjuvant treatment in advanced breast cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer

Evaluate response to neoadjuvant treatment in advanced breast cancer

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females ≥ 18 years up to 85 years old
* Individuals referred to hospitals for diagnosis of breast cancer
* Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance
* Availability of pathological report (surgical specimen)
* Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit)
* Availability of treatment response

Exclusion Criteria

* Patient with incomplete or low-quality data (radiological, pathological or clinical)

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.